Immunicum - Catalysts approaching for DCP-001




11.05.22 08:18
Edison Investment Research

Immunicum specialises in the research and development of novel immunotherapies that target hard-to-treat tumours and tumour recurrence. In its pipeline and strategic outlook presented in Q122, management highlighted its focus on developing DCP-001, a novel cancer relapse vaccine. The ongoing Phase II ADVANCE II trial (investigating DCP-001 as a monotherapy in acute myeloid leukaemia, or AML) will release multiple updates in 2022, providing potential catalysts for the shares. Importantly, complete minimal residual disease (MRD) data are expected to be announced in Q222, followed by survival data at the year end. Additionally, DCP-001 is in ongoing Phase I trials for treating ovarian cancer. At end-March 2022, the company had cash of SEK123m, which we expect to provide a runway to H123. In light of the refocused strategy, our estimates are under review.




 
 
hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
0,224 € 0,2125 € 0,0115 € +5,41% 20.05./22:00
 
ISIN WKN Jahreshoch Jahrestief
SE0005003654 A1W59F 0,59 € 0,17 €
Handelsplatz Letzter Veränderung  Zeit
Stuttgart 0,1998 € +8,47%  20.05.22
München 0,206 € +5,86%  20.05.22
Berlin 0,224 € +5,41%  20.05.22
Frankfurt 0,1946 € +4,96%  20.05.22
  = Realtime
Aktien des Tages
  

Jetzt für den kostenfreien Newsletter "Aktien des Tages" anmelden und keinen Artikel unseres exklusiven Labels AC Research mehr verpassen.

Das Abonnement kann jederzeit wieder beendet werden.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
  Immunicum: unique immuno-onco. 24.04.21
RSS Feeds




Bitte warten...